{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T04:02:46Z","timestamp":1726632166915},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,17]]},"DOI":"10.7759\/cureus.69575","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T16:57:27Z","timestamp":1726592247000},"source":"Crossref","is-referenced-by-count":0,"title":["Nivolumab-Induced Neuromyopathy: A Case Report"],"prefix":"10.7759","author":[{"given":"Tal","family":"Sharon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekrem","family":"Yetiskul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Khamis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"El Sayegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1175694","article-title":"Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers","volume":"12","author":"Rajan A","year":"2016","unstructured":"Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers. Hum Vaccin Immunother. 2016, 12:2219-31. 10.1080\/21645515.2016.1175694","journal-title":"Hum Vaccin Immunother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris RL","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, et al.. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016, 375:1856-67. 10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"key":"ref3","article-title":"Nivolumab","author":"Rendon A","year":"2023","unstructured":"Rendon A, Rayi A. Nivolumab. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer","volume":"42","author":"Baraibar I","year":"2019","unstructured":"Baraibar I, Melero I, Ponz-Sarvise M, Castanon E. Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer. Drug Saf. 2019, 42:281-94. 10.1007\/s40264-018-0774-8","journal-title":"Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi J","year":"2020","unstructured":"Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020, 20:e9. 10.4110\/in.2020.20.e9","journal-title":"Immune Netw"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez418","article-title":"Toxicities associated with checkpoint inhibitors-an overview","volume":"58","author":"Spiers L","year":"2019","unstructured":"Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford). 2019, 58:vii7-vii16. 10.1093\/rheumatology\/kez418","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03286-x","article-title":"Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report","volume":"16","author":"Saishu Y","year":"2022","unstructured":"Saishu Y, Yoshida T, Seino Y, Nomura T. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report. J Med Case Rep. 2022, 16:61. 10.1186\/s13256-022-03286-x","journal-title":"J Med Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw090","article-title":"Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barr\u00e9 syndrome: a case report","volume":"46","author":"Tanaka R","year":"2016","unstructured":"Tanaka R, Maruyama H, Tomidokoro Y, et al.. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barr\u00e9 syndrome: a case report. Jpn J Clin Oncol. 2016, 46:875-8. 10.1093\/jjco\/hyw090","journal-title":"Jpn J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds KL","year":"2019","unstructured":"Reynolds KL, Guidon AC. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist. 2019, 24:435-43. 10.1634\/theoncologist.2018-0359","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/290455-nivolumab-induced-neuromyopathy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T16:57:29Z","timestamp":1726592249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/290455-nivolumab-induced-neuromyopathy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.69575","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,17]]}}}